Literature DB >> 32556182

Colonoids From Patients With Pediatric Inflammatory Bowel Disease Exhibit Decreased Growth Associated With Inflammation Severity and Durable Upregulation of Antigen Presentation Genes.

Judith R Kelsen1, Noor Dawany2, Maire A Conrad1, Tatiana A Karakasheva1, Kelly Maurer3, Jane M Wei1, Selen Uman4, Maiah H Dent1, Rithika Behera1, Laura M Bryant1, Xianghui Ma1, Leticia Moreira5, Priya Chatterji6, Rawan Shraim1, Audrey Merz1, Rei Mizuno7, Lauren A Simon1, Amanda B Muir1, Claudio Giraudo8, Edward M Behrens9, Kelly A Whelan10, Marcella Devoto11,12, Pierre A Russo13, Sarah F Andres14, Kathleen E Sullivan3, Kathryn E Hamilton1.   

Abstract

BACKGROUND: Defining epithelial cell contributions to inflammatory bowel disease (IBD) is essential for the development of much needed therapies for barrier repair. Children with very early onset (VEO)-IBD have more extensive, severe, and refractory disease than older children and adults with IBD and, in some cases, have defective barrier function. We therefore evaluated functional and transcriptomic differences between pediatric IBD (VEO and older onset) and non-IBD epithelium using 3-dimensional, biopsy-derived organoids.
METHODS: We measured growth efficiency relative to histopathological and clinical parameters in patient enteroid (ileum) and colonoid (colon) lines. We performed RNA-sequencing on patient colonoids and subsequent flow cytometry after multiple passages to evaluate changes that persisted in culture.
RESULTS: Enteroids and colonoids from pediatric patients with IBD exhibited decreased growth associated with histological inflammation compared with non-IBD controls. We observed increased LYZ expression in colonoids from pediatric IBD patients, which has been reported previously in adult patients with IBD. We also observed upregulation of antigen presentation genes HLA-DRB1 and HLA-DRA, which persisted after prolonged passaging in patients with pediatric IBD.
CONCLUSIONS: We present the first functional evaluation of enteroids and colonoids from patients with VEO-IBD and older onset pediatric IBD, a subset of which exhibits poor growth. Enhanced, persistent epithelial antigen presentation gene expression in patient colonoids supports the notion that epithelial cell-intrinsic differences may contribute to IBD pathogenesis.
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  VEO-IBD; colonoids; enteroids; epithelial cells; inflammatory bowel disease

Mesh:

Year:  2021        PMID: 32556182      PMCID: PMC7813751          DOI: 10.1093/ibd/izaa145

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  35 in total

Review 1.  A nomenclature for intestinal in vitro cultures.

Authors:  Matthias Stelzner; Michael Helmrath; James C Y Dunn; Susan J Henning; Courtney W Houchen; Calvin Kuo; John Lynch; Linheng Li; Scott T Magness; Martin G Martin; Melissa H Wong; Jian Yu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-29       Impact factor: 4.052

2.  Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency.

Authors:  Brigid S Boland; Christella E Widjaja; Asoka Banno; Bing Zhang; Stephanie H Kim; Samantha Stoven; Michael R Peterson; Marilyn C Jones; H Irene Su; Sheila E Crowe; Jack D Bui; Samuel B Ho; Yoshinaga Okugawa; Ajay Goel; Eric V Marietta; Mahdieh Khosroheidari; Kristen Jepsen; Jose Aramburu; Cristina López-Rodríguez; William J Sandborn; Joseph A Murray; Olivier Harismendy; John T Chang
Journal:  J Immunol       Date:  2015-02-09       Impact factor: 5.422

3.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

Review 4.  JAK inhibitors: Novel developments in management of ulcerative colitis.

Authors:  Gionata Fiorino; Ferdinando D'Amico; Angelo Italia; Daniela Gilardi; Federica Furfaro; Silvio Danese
Journal:  Best Pract Res Clin Gastroenterol       Date:  2018-05-23       Impact factor: 3.043

5.  Class II antigen (HLA-DR) expression by intestinal epithelial cells in inflammatory diseases of colon.

Authors:  G B McDonald; D P Jewell
Journal:  J Clin Pathol       Date:  1987-03       Impact factor: 3.411

6.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

7.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis.

Authors:  K Geboes; R Riddell; A Ost; B Jensfelt; T Persson; R Löfberg
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

8.  In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture.

Authors:  Hiroyuki Miyoshi; Thaddeus S Stappenbeck
Journal:  Nat Protoc       Date:  2013-11-14       Impact factor: 13.491

9.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.

Authors:  Mark D Robinson; Davis J McCarthy; Gordon K Smyth
Journal:  Bioinformatics       Date:  2009-11-11       Impact factor: 6.937

10.  Biopsy-derived Intestinal Epithelial Cell Cultures for Pathway-based Stratification of Patients With Inflammatory Bowel Disease.

Authors:  Wiebe Vanhove; Kris Nys; Ingrid Arijs; Isabelle Cleynen; Manuel Noben; Sebastiaan De Schepper; Gert Van Assche; Marc Ferrante; Séverine Vermeire
Journal:  J Crohns Colitis       Date:  2018-01-24       Impact factor: 9.071

View more
  3 in total

1.  Tofacitinib Downregulates TNF and Poly(I:C)-Dependent MHC-II Expression in the Colonic Epithelium.

Authors:  Shreya Gopalakrishnan; Marianne Doré Hansen; Helene Kolstad Skovdahl; Ingrid Aass Roseth; Atle van Beelen Granlund; Ann Elisabet Østvik; Ingunn Bakke; Arne Kristian Sandvik; Torunn Bruland
Journal:  Front Immunol       Date:  2022-05-17       Impact factor: 8.786

Review 2.  Patient-derived organoids for therapy personalization in inflammatory bowel diseases.

Authors:  Marianna Lucafò; Antonella Muzzo; Martina Marcuzzi; Lorenzo Giorio; Giuliana Decorti; Gabriele Stocco
Journal:  World J Gastroenterol       Date:  2022-06-28       Impact factor: 5.374

Review 3.  Gastrointestinal epithelial innate immunity-regionalization and organoids as new model.

Authors:  Özge Kayisoglu; Nicolas Schlegel; Sina Bartfeld
Journal:  J Mol Med (Berl)       Date:  2021-02-04       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.